We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Domestic and foreign FDA inspections of biologic and drug manufacturing facilities declined for fiscal 2006, from 4,513 in 2005 to 4,237, according to a recent report from the Office of Regulatory Affairs.